Trial Profile
VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Volrubigene ralaparvovec (Primary)
- Indications Crigler-Najjar syndrome
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms VALENS
- Sponsors Astellas Gene Therapies
- 23 Feb 2021 Status changed from suspended to discontinued as per Sponsor Decision.
- 21 Jun 2019 Status changed from recruiting to suspended.
- 21 Jun 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2019.